The expression modifier score (EMS) v2 enhances regulatory variant prioritization via Enformer-derived features and multi-task learning
Yugo Takahashi, Qingbo S. Wang, Takanori Hasegawa, Ho Namkoong et autres
0 citationsCommunications Biology
Tomoki Kuge
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
62Publications signalées
648Citations signalées
3Affiliations récentes
Institutions déclarées
Domaines associés
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisLung Cancer Diagnosis and TreatmentMycobacterium research and diagnosis
Publications récentes
Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study
Kiyohide Komuta, Kinnosuke Matsumoto, Motohiro Tamiya, Takayuki Shiroyama et autres
0 citationsJTO Clinical and Research Reports
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
Kinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama, Tomoki Kuge et autres
1 citationEuropean Journal of Cancer
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non‐Squamous Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study
Keijiro Yamauchi, Kinnosuke Matsumoto, Takayuki Shiroyama, Akihiro Tamiya et autres
1 citationThoracic Cancer
Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy
Hirotomo Machiyama, Kinnosuke Matsumoto, Takayuki Shiroyama, Akito Miyazaki et autres
0 citationsRespiratory Medicine
Host control of persistent Epstein–Barr virus infection
A Schmidt, T. Madhusankha Alawathurage, Friederike S. David, Yosuke Ogawa et autres
6 citationsNature
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
Yuhei Kinehara, Kinnosuke Matsumoto, Takayuki Shiroyama, Kiyohide Komuta et autres
1 citationLung Cancer
Impact of Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors on Anti‐ PD ‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes
K. Matsumoto, Yujiro Naito, Takayuki Shiroyama, Motohiro Tamiya et autres
2 citationsCancer Science
Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study
Akito Miyazaki, Kinnosuke Matsumoto, Motohiro Tamiya, Kiyohide Komuta et autres
0 citationsJTO Clinical and Research Reports
Host control of persistent Epstein–Barr virus infection
Axel Schmidt, T. Madhusankha Alawathurage, Friederike S. David, Yosuke Ogawa et autres
0 citationsNature
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study
Nao Shoshihara, Kinnosuke Matsumoto, Takayuki Shiroyama, Kiyohide Komuta et autres
0 citationsLung Cancer
Corrigendum to “Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study” [Eur J Cancer. 2025;228:115748]
Akihiro Tsukaguchi, Kinnosuke Matsumoto, Akihiro Tamiya, Motohiro Tamiya et autres
1 citationEuropean Journal of Cancer
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.